Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Alexandria Expands With $26M Buyout In Stanford Research Park

Published 09/26/2019, 09:41 PM
Updated 07/09/2023, 06:31 AM

Alexandria Real Estate Equities (NYSE:ARE) recently announced the buyout of 3160 Porter Drive, a 92,000 rentable square feet (RSF) redevelopment project in Stanford Research Park, for $26 million. The transaction highlights the company’s efforts to expand presence in greater Stanford innovation cluster.

Notably, Stanford University selected Alexandria for turning the property into a dynamic innovation center that will promote growth of early- and growth-stage life science companies. This will aid in discovery and development of new treatments and cures.

The site will be home to Alexandria LaunchLabs at Stanford Research Park, which is likely to open in the first half of 2021. The full-service platform will offer member companies with flexible, move-in-ready office/laboratory space, mentorship and access to strategic investment capital through Alexandria’s seed-stage funding model.

Notably, Alexandria has played a significant role in the development of the expansive life science ecosystem in the San Francisco Bay Area. The company started with the buyout of key assets in 1996. Moreover, in 1999, the company acquired its first property in Stanford Research Park.

The company is making concerted efforts to grow the greater Stanford innovation cluster with the integration of life science and technology. Alexandria’s operating asset base within the greater Stanford innovation cluster comprises 1.1 million RSF. This includes 300,000 RSF of fully leased office/laboratory space in Stanford Research Park.

In this innovation cluster, Alexandria’s life science and technology tenants roster not only includes multinational pharmaceutical companies like Jazz Pharmaceuticals plc, and life science product, service and device companies such as Verb Surgical Inc. but also global technology companies like Alphabet (NASDAQ:GOOGL) Inc. (NASDAQ:GOOG) and Facebook, Inc. (NASDAQ:FB) , and institutional entities like Stanford University School of Medicine.

Further, Alexandria is well poised to grow through its capability to provide innovative entities with expansion opportunities close to public transportation networks. In fact, the company has an additional 1.6 million RSF of value-creation development projects targeted for delivery through 2022.

To tap opportunities in the life-science and technology real estate market, Alexandria is undertaking development and redevelopment projects. In fact, the company has 1.5 million RSF of Class A properties going through construction, with an estimated initial occupancy in 2019, as well as 9.2 million SF of near-term, intermediate-term and future development and redevelopment projects. The delivery of these new Class A properties in AAA locations is likely to boost the company’s operating performance.

Alexandria currently carries a Zacks Rank #2 (Buy). In the year-to-date period, shares of the company have surged 34.7%, outperforming the industry’s rally of 25.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.



Other Stock to Consider

Investors can also consider another top-ranked stock in the REIT space like Equity Residential (NYSE:EQR) . Equity Residential’s funds from operations (FFO) per share estimate for the current year moved up 0.3% to $3.45 over the past month. Additionally, it has an expected long-term growth rate of 6%.

Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Alphabet Inc. (GOOG): Free Stock Analysis Report

Facebook, Inc. (FB): Free Stock Analysis Report

Equity Residential (EQR): Free Stock Analysis Report

Alexandria Real Estate Equities, Inc. (ARE): Free Stock Analysis Report

Original post

Zacks Investment Research

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.